Diplomat Pharmacy (DPLO) Tops Q1 EPS by 1c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Diplomat Announces 1st Quarter Financial Results
May 11, 2015 4:07 PM EDTFLINT, Mich., May 11, 2015 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended March 31, 2015. All comparisons, unless otherwise noted, are to the quarter ended March 31, 2014.
First Quarter 2015 Highlights include:
Revenue of $625 million, an increase of 34% Total prescriptions dispensed of 194,000, an increase of 6% Gross margin of 6.6% versus 6.3% Adjusted EBITDA of $11.2 million, an increase of 36% Adjusted EPS of $0.09, versus $0.05... More


